Rohin Mhatre
Fortune : 684 110 $ au 30/06/2026
Fortune : 684 110 $ au 30/06/2026
Dr. Rohin Mhatre is a Chief Technical Operations Officer at Parabilis Medicines, Inc. and an Independent Director at Repligen Corp.
He is on the Board of Directors at Repligen Corp.
Dr. Mhatre was previously employed as a Senior VP-Product & Technology Development by Biogen, Inc. He received his doctorate degree from Northeastern University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REPLIGEN CORPORATION 0,01 % | 14/05/2026 | 5 014 ( 0,01 % ) | 684 110 $ | 30/06/2026 |
| 10/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| REPLIGEN CORPORATION | Directeur/Membre du Conseil | 01/03/2020 |
| PARABILIS MEDICINES, INC. | Directeur Technique/Scientifique/R&D | 01/10/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/08/2023 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Repligen Corp.
Repligen Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures biologic drugs | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Parabilis Medicines
Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national